Genetron Holdings Limited (GTH)
Stock Price:
$13.01 USD
1.17 (9.88%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.18B |
| Revenue (ttm) |
46.20M |
| Net Income (ttm) |
-96.58M |
| Shares Out |
88.36M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$13.01 |
| Previous Close |
$11.84 |
| Change ($) |
1.17 |
| Change (%) |
9.88% |
| Day's Open |
11.91 |
| Day's Range |
11.91 - 13.38 |
| Day's Volume |
574,451 |
| 52-Week Range |
11.09 - 17.71 |
More Stats
| Market Cap |
1.18B |
| Enterprise Value |
1.15B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
88.36M |
| Float |
17.43M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-0.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
25.56 |
| PB Ratio |
n/a |
| Revenue |
46.20M |
| Operating Income |
-43.84M |
| Net Income |
-96.58M |
| Free Cash Flow |
-30.48M |
| Net Cash |
27.79M |
| Net Cash / Share |
0.31 |
| Gross Margin |
44.83% |
| Operating Margin |
-94.88% |
| Profit Margin |
-209.00% |
| FCF Margin |
-65.96% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-280.20% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions CNY.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 323 | 225 | 101 |
| Revenue Growth | 43.63% | 122.87% | - |
| Gross Profit | 145 | 92.73 | 26.82 |
| Operating Income | -307 | -233 | -153 |
| Net Income | -676 | -465 | -421 |
| Shares Outstanding | 442 | - | - |
| Earnings Per Share | -27.05 | -20.45 | -23.20 |
| Operating Cash Flow | -197 | -201 | -130 |
| Capital Expenditures | -16.38 | -43.91 | -19.17 |
| Free Cash Flow | -213 | -245 | -149 |
| Cash & Equivalents | 262 | 101 | 295 |
| Total Debt | 67.64 | - | - |
| Net Cash / Debt | 195 | 101 | 295 |
| Assets | 574 | 324 | 441 |
| Liabilities | 2,352 | 1,388 | 1,064 |
| Book Value | -1,778 | -1,064 | -622 |
Numbers in millions CNY, except per-share numbers.
Company Details
| Full Name |
Genetron Holdings Limited |
| Country |
China |
| Employees |
697 |
| CEO |
Si Zhen Wang |
Stock Information
| Ticker Symbol |
GTH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: GTH |
| IPO Date |
June 19, 2020 |
Description
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.